LEADER 04312nam 2201285z- 450 001 9910404084403321 005 20231214133259.0 010 $a3-03928-759-1 035 $a(CKB)4100000011302294 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/61309 035 $a(EXLCZ)994100000011302294 100 $a20202102d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aTreatment Strategies and Survival Outcomes in Breast Cancer 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (264 p.) 311 $a3-03928-758-3 330 $aTreatment strategies for breast cancer are wide-ranging and often based on a multi-modality approach, depending on the stage and biology of the tumour and the acceptance and tolerance of the patient. They may include surgery, radiotherapy, and systemic therapy (endocrine therapy, chemotherapy, and targeted therapy). Advances in technologies such as oncoplastic surgery, radiation planning and delivery, and genomics, and the development of novel systemic therapy agents alongside their evaluation in ongoing clinical trials continue to strive for improvements in outcomes. In this Special Issue, we publish a collection of studies looking at all forms of therapeutic strategies for early and advanced breast cancer, focusing on their outcomes, notably survival. 610 $arelative survival 610 $ayoung women 610 $acancer treatment 610 $afulvestrant 610 $alapatinib 610 $atumor biology 610 $aantihormone therapy 610 $amastectomy 610 $aaromatase inhibitors 610 $achemotherapy 610 $aserum biomarker 610 $acyclin E 610 $aanthracycline resistance 610 $azero-inflated Poisson regression model 610 $alymph-node ratio 610 $aCHEK2 610 $acomparative effectiveness 610 $abreast-conserving therapy 610 $ataxane sensitivity 610 $aliquid biopsy 610 $aHER2 c-erbB2 610 $acolorectal cancer 610 $ainfiltrating breast cancer 610 $asurvival 610 $aexercise characteristics 610 $alactate dehydrogenase 610 $abiomarker 610 $abreast cancer survivors 610 $aBRCA 610 $adisease-free survival 610 $aPIK3CA 610 $ametastatic breast cancer 610 $acell-free DNA 610 $ainvasive breast cancer 610 $aradiotherapy 610 $aMetformin 610 $asocial well-being 610 $agene expression 610 $acontralateral breast cancer 610 $abasal-like breast cancer 610 $aLMK-235 610 $aSrc kinase 610 $aHER2/neu 610 $aLKB1 610 $aOlder women 610 $aLDH 610 $amutation carriers 610 $astage IV 610 $amammography screening 610 $aNCDB 610 $acMet 610 $aSEER 610 $apertuzumab 610 $aphysical function 610 $aoutcome 610 $aribociclib 610 $aolder patients 610 $ageriatric oncology 610 $ametastatic 610 $aoverdiagnosis 610 $anext-generation sequencing 610 $aabemaciclib 610 $aEndocrine therapy 610 $amonitoring metastatic breast cancer 610 $abreast cancer 610 $acirculating tumor cells 610 $aBreast Cancer 610 $aPALB2 610 $ahistone deacetylase 610 $aprognosis 610 $aphysical activity 610 $atrastuzumab 610 $aductal carcinoma in situ 610 $acontralateral prophylactic mastectomy 610 $aERCC1 610 $afamily history 610 $aT-DM1 610 $aATM 610 $aadvanced breast cancer 610 $aincidence 610 $apalbociclib 610 $aHDAC5 inhibitors 610 $aAPOBEC3B 700 $aCheung$b Kwok-Leung$4auth$01325396 906 $aBOOK 912 $a9910404084403321 996 $aTreatment Strategies and Survival Outcomes in Breast Cancer$93036843 997 $aUNINA